Guillermo Quintero

Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study

Mercedes Salgado, A. García, Elvira Buxó et al. · BMC Cancer · 2018 · 35 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected

Javier Sastre, Virginia de la Orden, Antonio Martínez et al. · Clinical Colorectal Cancer · 2020 · 30 citations

Medicine, Cancer Biology, Oncology +17

Different outcomes for transplant-eligible newly diagnosed multiple myeloma patients in Latin America according to the public versus private management: a GELAMM study

Camila Peña, Eloísa Riva, Natalia Schütz et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2020 · 28 citations · Full text

Medicine, Hematology, Oncology +14

Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study

Javier Sastre, Pilar García‐Alfonso, José María Viéitez et al. · ESMO Open · 2021 · 25 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRASmetastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study)

Julen Fernández-Plana, Carles Pericay, Guillermo Quintero et al. · BMC Cancer · 2014 · 23 citations · Full text

Medicine, Oncology, Pharmacology +14